EU Suspends Modified-Release Products with Paracetamol

News
Article

EMA recommends suspending the marketing of modified- or prolonged-released products containing paracetamol due to a difficulty in managing overdose.

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) announced on Dec. 15, 2017 that it was recommending the suspension of modified- or prolonged-released products containing paracetamol. The recommendation was made after it was determined that the risk of overdose outweighed the benefits of longer-acting product.

Europe’s Co-ordination Group for Mutual Recognition and Decentralised Procedures–Human (CMDh) agreed with the advice, stating there was no proved way to adapt the management of overdose across the European Union to cover both immediate- and modified-release paracetamol drugs. “The CMDh therefore endorsed the PRAC recommendation that the marketing authorizations for medicines containing modified-release paracetamol, alone or combined with the opioid medicine tramadol, should be suspended,” EMA stated in a press release.

EMA plans to suspend marketing authorization of such products until companies can provide the agency with practical EU-wide measures to prevent overdose of the drugs. Immediate-release paracetamol products are not affected by the review and will continue to be available.

Source: EMA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.